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ABSTRACT Both intracellular immune sensing and extracellular innate immune
sensing have been implicated in initiating macrophage proinﬂammatory cytokine re-
sponses to Streptococcus pneumoniae. The S. pneumoniae capsule, a major virulence
determinant, prevents phagocytosis, and we hypothesized that this would reduce
activation of host innate inﬂammatory responses by preventing activation of intra-
cellular proinﬂammatory signaling pathways. We investigated this hypothesis in hu-
man monocyte-derived macrophages stimulated with encapsulated or isogenic un-
encapsulated mutant S. pneumoniae. Unexpectedly, despite strongly inhibiting
bacterial internalization, the capsule resulted in enhanced inﬂammatory cytokine
production by macrophages infected with S. pneumoniae. Experiments using puriﬁed
capsule material and a Streptococcus mitis mutant expressing an S. pneumoniae sero-
type 4 capsule indicated these differences required whole bacteria and were not
due to proinﬂammatory effects of the capsule itself. Transcriptional proﬁling demon-
strated relatively few differences in macrophage gene expression proﬁles between
infections with encapsulated S. pneumoniae and those with unencapsulated S. pneu-
moniae, largely limited to reduced expression of proinﬂammatory genes in response
to unencapsulated bacteria, predicted to be due to reduced activation of the NF-B
family of transcription factors. Blocking S. pneumoniae internalization using cytochalasin
D had minimal effects on the inﬂammatory response to S. pneumoniae. Experiments us-
ing murine macrophages indicated that the affected genes were dependent on Toll-like
receptor 2 (TLR2) activation, although not through direct stimulation of TLR2 by capsule
polysaccharide. Our data demonstrate that the early macrophage proinﬂammatory re-
sponse to S. pneumoniae is mainly dependent on extracellular bacteria and reveal an un-
expected proinﬂammatory effect of encapsulated S. pneumoniae that could contribute to
disease pathogenesis.
IMPORTANCE Multiple extra- and intracellular innate immune receptors have been
identiﬁed that recognize Streptococcus pneumoniae, but the relative contributions of
intra- versus extracellular bacteria to the inﬂammatory response were unknown. We
have shown that intracellular S. pneumoniae contributes surprisingly little to the in-
ﬂammatory responses, with production of important proinﬂammatory cytokines
largely dependent on extracellular bacteria. Furthermore, although we expected the
S. pneumoniae polysaccharide capsule to block activation of the host immune sys-
tem by reducing bacterial internalization and therefore activation of intracellular in-
nate immune receptors, there was an increased inﬂammatory response to encapsu-
lated compared to unencapsulated bacteria, which is likely to contribute to disease
pathogenesis.
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Streptococcus pneumoniae is an important bacterial cause of otitis media, pneumo-nia, septicemia, and meningitis, resulting in signiﬁcant worldwide morbidity and
mortality (1). S. pneumoniae causes a rapid and robust inﬂammatory response, includ-
ing production of the key cytokines tumor necrosis factor (TNF), interleukin-1 (IL-1),
and IL-6, which are critical for protective immunity (2–13). However, this inﬂammatory
response can also contribute to pathogenesis: for example, by causing pulmonary
consolidation, acute respiratory distress syndrome (ARDS), and septic shock and, in
patients with meningitis, chronic neurological damage (14–16). Multiple mechanisms
have been described that contribute to the inﬂammatory response to S. pneumoniae,
including both intracellular and extracellular pathogen recognition receptors (PRRs).
Extracellular PRRs activated by S. pneumoniae include Toll-like receptor 2 (TLR2 [by
bacterial lipoproteins]) (17), TLR4 (by pneumolysin) (18), and the scavenger receptor
MARCO (19). More recently, there has been considerable interest in activation of
intracellular PRRs by S. pneumoniae. These include activation of the inﬂammasome by
the pore-forming toxin pneumolysin (20), nucleotide-binding oligomerization domain
(NOD) receptors by peptidoglycan (21, 22), and nucleic acid receptors such as cGAS (23)
and RIG-I-like receptors (RLRs) (24). In addition, TLRs are also located in phagosome
membranes, and can be activated by phagocytosed bacteria (25–27). A similar range of
PRRs are involved in the inﬂammatory response to other extracellular bacterial patho-
gens; the macrophage-dependent inﬂammatory response to S. aureus has been shown
to be dependent on both extracellular and internalized bacteria (25). However, the
relative contributions to the macrophage inﬂammatory response of activation of
intracellular PRRs by internalized S. pneumoniae versus activation of cell surface PRRs by
extracellular bacteria have not been deﬁned.
The most important S. pneumoniae virulence factor is the capsule, a polysaccharide
layer that surrounds the bacterium and profoundly inhibits phagocytosis as well as
preventing bacterial entrapment by respiratory mucus and killing by neutrophil extra-
cellular traps (28–31). As unencapuslated S. pneumoniae strains are much more sus-
ceptible to phagocytosis than otherwise isogenic encapsulated strains (29, 32), com-
paring phagocyte inﬂammatory responses to unencapsulated and encapsulated S.
pneumoniae may identify the relative importance of intracellular signaling pathways
for inﬂammatory responses. In contrast to cell wall and membrane components,
previously published data suggest that puriﬁed capsular polysaccharide does not
stimulate an inﬂammatory response. Puriﬁed capsular material only induces low
levels of inﬂammation in a rabbit meningitis model (33), in human whole blood (34),
and in RAW murine macrophages (35). These weak responses may be caused by
residual contamination of capsular material with proinﬂammatory cell wall and
membrane components (36). As the capsule surrounds the bacterium and blocks
phagocytosis, the capsule could also affect inﬂammation by blocking interaction of
cell surface TLRs to S. pneumoniae ligands. Hence the capsule could potentially alter
inﬂammatory responses to S. pneumoniae by reducing activation of both intracel-
lular and cell surface PRRs. These questions have not previously been addressed
despite the importance of both the capsule and inﬂammatory responses to S.
pneumoniae disease pathogenesis.
Using in vitro infection of monocyte-derived macrophages (MDMs) with encapsu-
lated and unencapsulated bacteria, supported by data from a mouse pneumonia
model, we have investigated the relative contributions of macrophage cell surface and
intracellular PRRs to the macrophage inﬂammatory response to S. pneumoniae. We
hypothesized that intracellular PRRs would make a signiﬁcant contribution to the
inﬂammatory response to S. pneumoniae, such that the capsule would contribute to
immune evasion by reducing the inﬂammatory response as a result of diminished
bacterial phagocytosis.
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RESULTS
Loss of the S. pneumoniae capsule increases internalization by macrophages.
Previously we demonstrated that the capsule inhibits neutrophil phagocytosis of S.
pneumoniae (29). Flow cytometry, microscopy, and antibiotic protection assays were
used to conﬁrm that loss of the capsule also increases S. pneumoniae phagocytosis by
macrophages. In ﬂow cytometry assays, the unencapsulated TIGR4 Δcps bacteria were
more rapidly associated with RAW macrophages than wild-type (WT) TIGR4 bacteria
(Fig. 1A and B). Differences were evident after 15 min of incubation and were present
whether bacteria were unopsonized or opsonized with complement-inactivated serum
or normal human serum. Antibiotic protection assays conﬁrmed that in 5% human
serum, the percentage of adherent bacteria internalized by human MDMs after 2 h was
nearly 10-fold greater for the TIGR4 Δcps strain than that of WT TIGR4 (P  0.0001)
(Fig. 1C). This was supported by microscopy, which showed a 2-fold increase in uptake
of unencapsulated bacteria (P 0.042) (Fig. 1D to F) at 2 h. However, once internalized,
there was no signiﬁcant difference in the intracellular survival of TIGR4 and TIGR4 Δcps
bacteria when measured by antibiotic protection assays using cells of the human
macrophage cell line THP-1 (Fig. 1G). Comparative intracellular survival experiments
were not performed with MDMs as inherent interdonor variability in bacterial uptake
prevents identiﬁcation of bacterial numbers that consistently lead to the internalization
of similar numbers of TIGR4 and TIGR4 Δcps bacteria. The increase in macrophage
phagocytosis allowed MDMs to control TIGR4 Δcps bacterial numbers, whereas after
6 h, signiﬁcantly more TIGR4 CFU were recovered from culture supernatants (Fig. 1H).
Overall, these data demonstrate that incubation of unencapsulated S. pneumoniae with
MDMs results in substantial increases in the numbers of intracellular bacteria compared
to incubation with encapsulated bacteria, but without signiﬁcantly affecting the dy-
namics of intracellular killing.
Comparison of the MDM transcriptional responses to encapsulated and unen-
capsulated S. pneumoniae. Although puriﬁed serotype 4 polysaccharide induced
MDM inﬂammatory cytokine secretion, this was largely abrogated by neutralization
of contaminating lipopolysaccharide (LPS) using polymyxin B (Fig. 2A and B). To
assess whether the capsule directly inﬂuences macrophage inﬂammatory response
to external bacteria, MDMs were incubated with a Streptococcus mitis mutant strain
expressing the S. pneumoniae serotype 4 capsule (37). Expression of the serotype 4
capsule by S. mitis did not enhance the MDM inﬂammatory response compared to
the wild type or an unencapsulated mutant strain (Fig. 2C and D). These data show
the capsule had limited direct effects on MDM inﬂammatory responses, and there-
fore we could exploit the increased phagocytosis of unencapsulated S. pneumoniae
to compare the effects of internalized versus extracellular bacteria on the MDM
response to S. pneumoniae.
Microarrays were used to compare genome-wide transcriptional responses to MDM
infection with either the TIGR4 or TIGR4 Δcps strain (Fig. 3A). Overall, 294 genes showed
increased expression in response to infection with either S. pneumoniae strain (Fig. 3A).
Of these, a subset of 100 genes were upregulated in response to TIGR4 alone, 104
genes were upregulated in response to the TIGR4 Δcps strain alone, and 194 genes
were upregulated in response to both strains. As previously reported by us (17), the
MDM genes that showed the greatest degree of upregulation in response to TIGR4
included those coding for the proinﬂammatory cytokines TNF, IL-23A, IL-6, IL-1, and
IL-8, along with a range of chemokines, and closely mirrored the MDM response to the
TLR2 agonist PAM2CSK4 (Fig. 3B). Unexpectedly, the upregulation of many of these
genes was substantially lower when MDMs were infected with the TIGR4 Δcps strain.
Differences in MDM transcripts upregulated after S. pneumoniae infection between the
TIGR4 and TIGR4 Δcps strains showed a partial attenuation in the proinﬂammatory
subset of responses. This mirrored the attenuated response to the TIGR4 Δlgt strain that
lacks lipoproteins required for activation of TLR2 (17). Bioinformatic analysis of this
subset by gene ontology showed that these were enriched for secreted inﬂammatory
cytokines (Fig. 3C). Transcription factor binding site analysis inferred that these genes
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were primarily under the control of the NF-B family (Fig. 3D). Hence, despite resulting
in enhanced phagocytosis and internalization by MDMs, loss of the capsule speciﬁcally
results in reduced proinﬂammatory MDM transcriptional responses to infection with S.
pneumoniae.
FIG 1 (A and B) RAWmacrophages were incubated with FAM-SE-labeled bacteria preincubated in PBS, heat-inactivated (HK) serum, or 10%
pooled human serum. Cells were washed at 2 time points and then lifted and analyzed by ﬂow cytometry to assess association. The results
of 4 experiments are displayed as means standard errors of the means (SEM) at (A) 15 min or (B) 60 min, with TIGR4 data shown as gray
bars and TIGR4 Δcps data as white bars, as analyzed by t test. (C) MDMs incubated with bacteria at an MOI of 10 had an antibiotic protection
assay performed after 2 h, and data were analyzed by t test, with means  SEM from 3 experiments displayed. WT TIGR4 data are shown
as black bars and TIGR4 Δcps data as gray bars. (D to F) High-throughput imaging of ﬂuorescent TIGR4 and TIGR4 Δcps labeled with green
ﬂuorophore and incubated for 2 h with MDMs (nuclei in blue), with external bacteria labeled with anti-human IgG (labeled red) appearing
yellow (red arrow) due to the interaction of red and green ﬂuorophores, whereas internalized bacteria remain green (white arrow). Sample
images of MDMs incubated with TIGR4 and TIGR4 Δcps are shown in panels E and F, respectively. (G) Numbers of external and internal
bacteria were counted, and data are displayed as means  SEM from 3 experiments, with analysis by unpaired t test. WT TIGR4 data are
shown as black bars and TIGR4 Δcps data as gray bars. (G) Once TIGR4 and TIGR4 Δcps were internalized, with inocula adjusted such that
internalized bacteria at time zero were similar, numbers of surviving internal bacteria were measured by antibiotic protection assay using
THP-1 cells. Results are displayed as means  SEM from 5 experiments at each time point, as analyzed by unpaired t test. WT TIGR4 data
are displayed as squares joined by a solid line and TIGR4 Δcps data as circles joined by a dotted line. (H) Bacteria were incubated with MDMs
at an MOI of 10, and MDM supernatant was plated at speciﬁed time points, displayed as the median and range from 6 experiments, with
WT TIGR4 data shown as black bars and TIGR4 Δcps data as gray bars, with counts analyzed by the Mann-Whitney U test.
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Encapsulated bacteria stimulate stronger MDM inﬂammatory cytokine re-
sponses. To validate the changes to transcriptional responses to the TIGR4 Δcps strain
at the protein level, TNF, IL-1, and IL-6 cytokine levels were measured in cell culture
supernatants of MDMs incubated with the TIGR4 or the TIGR4 Δcps strain. After 6 h,
MDMs showed a dose-dependent increase in TNF responses to TIGR4 but not to TIGR4
Δcps, with markedly higher levels of TNF in response to TIGR4 compared to TIGR4 Δcps
at multiplicities of infection (MOI) of greater than 10 (Fig. 4A). The TNF response to an
MOI of 100 for the TIGR4 Δcps strain was lower than that to an MOI of 10 or 1 for the
TIGR4 strain. Nonsigniﬁcant differences in TNF levels persisted between TIGR4 and
TIGR4 Δcps infected MDMs 12 and 24 h after infection (Fig. 4B). After 6 h, there was little
IL-1 release from MDMs at multiple MOI, but by 12 h, MDMs showed increased IL-1
production in response to the TIGR4 strain compared to TIGR4 Δcps (Fig. 4C and D).
Release of IL-6 decreased with increasing MOI for both strains; TIGR4 induced more IL-6
than TIGR4 Δcps only at an MOI of 1, with no signiﬁcant differences between the strains
with higher MOIs and later time points (Fig. 4E and F). Overall, these data complement
the transcriptional response results by demonstrating that the encapsulated TIGR4
strain stimulated a stronger MDM inﬂammatory cytokine response than the unencap-
sulated TIGR4 Δcps strain, with major differences in production of TNF and some
differences in IL-6 and IL-1.
The TIGR4 strain induces stronger early TNF responses in a mouse model of
pneumonia. A murine model of pneumonia (17, 32) was used to assess whether the
FIG 2 Direct effects of capsule on inﬂammatory responses. (A and B) MDMs were incubated with PPS (solid bars)
with or without 30 g/ml polymyxin B (PMxB) (checked bars), and TNF (A) and IL-6 (B) were measured. LPS at
100 ng/ml was used as a positive control, with and without addition of PMxB, and both sets of experiments are
represented as means  SEM from 3 experiments. Analysis was by 2-way ANOVA and Tukey’s multiple-
comparison test. (C and D) MDMs were incubated with the S. mitis WT, S. mitis Δcps mutant, or an S. mitis strain
expressing the S. pneumoniae serotype 4 capsule at an MOI of 10. PAM2CSK4 at 100 ng/ml (Cell Signaling) was
used as a positive control. TNF (C) and IL-6 (D) supernatant concentrations were measured after 6 h and are shown
as means  SEM from three separate experiments. The data were analyzed using 1-way ANOVA and Bonferroni
multiple-comparison test.
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differences seen in cell culture in TNF responses to S. pneumoniae reﬂected differences
during disease. After high-dose infection (5 106 CFU per mouse), bronchoalveolar
lavage ﬂuid (BALF) TNF levels recovered at 2 h and IL-1 and IL-6 at 4 h were higher in
response to the TIGR4 strain compared to infection with the TIGR4 Δcps strain (Fig. 5A
to C). However, as previously described (32), the capsule played an important role in
bacterial clearance, with markedly reduced levels of TIGR4 Δcps CFU recovered in BALF
(Fig. 5D). These differences in bacterial CFU in BALF confound interpretation of differ-
ences in cytokine responses. To partially account for this, experiments were repeated
using the nonreplicating ΔpabB mutant TIGR4 and TIGR4 Δcps strains to ensure BALF
TNF responses reﬂect differences to the initial bacterial inoculum. Using ΔpabB strains,
there was still an increased BALF TNF response to the encapsulated TIGR4 strain (Fig. 5E
 0
FIG 3 Whole-genome transcriptomic analysis was undertaken of MDMs incubated with TIGR4, TIGR4 Δcps, or TIGR4 Δlgt at an MOI of 10 or
controls with medium only, PAM2CSK4 at 100 ng/ml (Cell Signaling), or LPS at 100 ng/ml (Cell Signaling), all at 4 h. Some cells were preincubated
with 10 M cytochalasin D for 30 min prior to the addition of bacteria. (A) Correlation of fold change (FC) in expression of genes in MDMs
stimulated with TIGR4 or TIGR4 Δcps. Here, each point represents a gene, with the genes attenuated due to TIGR4 Δcps in comparison to those
of WT TIGR4 represented in green. (B) All the genes expressed at a signiﬁcantly higher level (P  0.05, FC of 1.5) by WT TIGR4-stimulated MDMs
in comparison to TIGR4 Δcps-stimulated MDMs, as calculated by t test. Each column represents an individual experiment, with 6 donors each for
unstimulated and the TIGR4- and TIGR4 Δcps-stimulated groups and 3 each for all other conditions. (C) Network diagram illustrating the most
signiﬁcantly enriched gene ontologies from panel A, where blue nodes are genes, red nodes are biological processes, green nodes are molecular
functions, and amber nodes are the cellular compartment. (D) Transcription factor binding site analysis for the transcriptional responses
attenuated by TIGR4 Δcps, showing transcription factor binding sites that are signiﬁcantly enriched in the responses attenuated in the absence
of capsule. This is plotted as the number of genes that each transcription factor is predicted to be activated by against the Z score, a statistical
measure of degree of overrepresentation over background.
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and F). To conﬁrm that BALF TNF responses reﬂected alveolar macrophage interactions
with S. pneumoniae and to try and reduce CFU differences between the strains,
low-dose infection (5 105 CFU) experiments were performed in mice treated with
intranasal liposomal clodronate 72 h prior to infection, which depletes approximately
85% of alveolar macrophages (32). Although macrophage depletion resulted in higher
CFU in BALF (Fig. 5G), both 2- and 4-h BALF TNF levels were markedly reduced in
response to the TIGR4 strain (Fig. 5H). These data conﬁrm that in a murine pneumonia
model, there is an increased early TNF response to infection with encapsulated S.
pneumoniae compared to unencapsulated bacteria, which is largely dependent on
alveolar macrophages.
FIG 4 MDMs were incubated with TIGR4 or TIGR4 Δcps for 6 h at various MOI, and supernatant was
analyzed for (A) TNF, (C) IL-1, and (E) IL-6, with TIGR4 data displayed as black bars and TIGR4 Δcps data
as gray bars. The data are displayed as means  SEM from at least 3 separate experiments, as analyzed
by unpaired t test. MDMs were incubated with TIGR4 or TIGR4 Δcps at an MOI of 10, and supernatant was
analyzed at various time points for (B) TNF, (D) IL-1, and (F) IL-6. TIGR4 data are shown as black bars and
TIGR4 Δcps data as gray bars, and the data are displayed as means  SEM from 3 experiments, as
analyzed by unpaired t test.
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MDM TNF responses to S. pneumoniae are largely dependent on extracellular
bacteria. The above data suggest that MDM TNF responses to S. pneumoniae are not
dependent on internalized bacteria. To conﬁrm this and identify how long MDMs need
to be exposed to S. pneumoniae to stimulate an effective inﬂammatory response, MDMs
FIG 5 (A to D) Six-week-old female CD1 mice were infected with 5 106 CFU of either TIGR4 or TIGR4 Δcps, with 6 mice in each group.
At various time points, mice were sacriﬁced, and BALF was retrieved and analyzed for (A) TNF, (B) IL-1, and (C) IL-6. The results were
analyzed by unpaired t test. (D) Bacterial CFU in BALF was measured at the same time points, as analyzed by Mann-Whitney U test. (E and
F) Six-week-old female CD1 mice were infected with 5 106 CFU of either TIGR4 Δpab or TIGR4 Δcps Δpab, with 6 mice in each group, and
after 2 h, mice were sacriﬁced and BALF was retrieved and analyzed for (E) TNF levels, as analyzed by unpaired t test, and (F) bacterial CFU
in BALF was measured at the same time points, as analyzed by Mann-Whitney U test. (G and H) Six-week-old female CD1 mice were given
intranasal liposomes or liposomal clodronate 72 h prior to infection with 5 105 CFU of either TIGR4 or TIGR4 Δcps, with 6 mice in each
group. After 2 and 4 h, mice were sacriﬁced and BALF was retrieved for (G) bacterial CFU, as analyzed by Kruskal-Wallis test with Dunn’s
multiple-comparison test and (H) TNF levels, as analyzed by 1-way ANOVA and Tukey’s multiple-comparison test. Black bars represent TIGR4
data and gray bars TIGR4 Δcps data, with data from clodronate-treated mice shown as checked bars (as seen in panels G and H). For panels
D and G, white boxes and whisker plots represent TIGR4 and gray ones TIGR4 Δcps, with data from clodronate-treated mice in checked bars.
In panel F, TIGR4 Δpab data are displayed as white whisker plots, with TIGR4 Δcps Δpab data as gray plots.
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were incubated with S. pneumoniae TIGR4 and then treated with gentamicin to kill
extracellular bacteria after phagocytosis of a signiﬁcant number of bacteria had already
occurred. There was no signiﬁcant 4-h TNF response by MDMs exposed to extracellular
TIGR4 for only 30 min, whereas 4 h of exposure stimulated a signiﬁcant TNF response
that persisted for 24 h and was consistently increased in response to the TIGR4 strain
compared to the TIGR4 Δcps strain (Fig. 6A and B). In contrast, 4 h of exposure of MDMs
to TIGR4 resulted only in very low levels of supernatant IL-1 and IL-6, possibly because
production of these cytokines in general needs a more prolonged stimulus (see Fig. S1A
and B in the supplemental material). To further investigate the relationship between
intra- and extracellular bacteria and the macrophage inﬂammatory response, MDM
infection experiments were repeated with the addition of cytochalasin to block phago-
cytosis. Cytochalasin at a concentration of 10 M inhibited S. pneumoniae phagocytosis
by MDMs (Fig. 6C to E). Despite this, cytochalasin did not reduce MDM supernatant TNF,
IL-6 (Fig. 6F and G), and IL-1 (not shown) responses to infection with either the TIGR4
or the TIGR4 Δcps strain, with most responses actually showing non-statistically signif-
icant increases. Opsonization of S. pneumoniae with human serum increased phagocy-
tosis and internalization of bacteria (29) but reduced supernatant levels of TNF and
IL-1 and abrogated differences between the wild-type and unencapsulated strains
(Fig. 6H and I). These data suggest that the MDM inﬂammatory response to S. pneu-
moniae is largely driven by extracellular rather than intracellular bacteria.
Transcriptional analysis was used to assess in detail the effects of blocking phago-
cytosis on MDM response to encapsulated and unencapsulated S. pneumoniae. Incu-
bating MDMs with cytochalasin D had relatively minor effects on the overall MDM
transcriptional response to S. pneumoniae, although overall there was a general in-
crease in inﬂammatory gene expression with preservation of the differences between
the TIGR4 and TIGR4 Δcps strains (Fig. 7A). There was little upregulation and few major
differences elicited between strains in the expression of the anti-inﬂammatory cytokine
genes coding for IL-10 or transforming growth factor  (TGF-) (Fig. 7A). Quantitative
PCR (qPCR) indicated small increases in expression of the IL-1 and IL-6 genes but not
TNF transcripts after MDMs were treated with cytochalasin D, but with preservation of
the large differences between the TIGR4 and TIGR4 Δcps strains (Fig. 7B to D). Overall,
these data conﬁrm that the MDM proinﬂammatory cytokine responses to S. pneu-
moniae are largely dependent on extracellular bacteria.
MDM responses to other unencapsulated strains and role of TLR2 activation.
The cytochalasin D data demonstrated that increased MDM inﬂammatory responses
when infected with the TIGR4 strain compared to the TIGR4 Δcps strain persisted even
after phagocytosis was blocked. To assess whether the effects of the capsule on
inﬂammatory responses were restricted to TIGR4, MDMs were incubated with the wild
type and unencapsulated mutants for three further S. pneumoniae strains, including
recent clinical capsular serotype 6B and 23F isolates. There were signiﬁcantly higher
levels of TNF and IL-6 in supernatants when MDMs were incubated with the wild type
in comparison to unencapsulated bacteria for two serotypes (2 and 6B), but not for
serotype 23F (Fig. 8A and B). These data show that encapsulated S. pneumoniae strains
are more proinﬂammatory than unencapsulated strains for multiple (although not all)
serotypes, and the role of the central TLR2 pathway in this effect was explored in more
detail.
Infection of murine bone marrow-derived macrophages (BMDMs) with TIGR4 strains
demonstrated that macrophage TNF and IL-6 responses to S. pneumoniae were, as
expected (17), highly dependent on TLR2. Although differences in the TNF responses
between TIGR4 and TIGR4 Δcps strains were lost after infection of TLR2/ macro-
phages (Fig. 9A and B), the TIGR4 and TIGR4 Δcps strains both stimulated a TLR2
reporter assay to a similar degree and puriﬁed serotype 4 capsular polysaccharide (PPS)
had no effect (Fig. 9C). These results indicate that although the macrophage cytokine
response to S. pneumoniae is dependent on TLR2, the capsule does not directly affect
TLR2 activation. Pneumolysin has multiple effects on immune responses to S. pneu-
moniae, including inﬂuencing inﬂammatory responses (20), and could be a confound-
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FIG 6 (A) MDMs were incubated with bacteria for 30 min at an MOI of 10, then medium or gentamicin was added, and
supernatant was analyzed after 4 h for TNF levels. The TIGR4 response is displayed as a black bar, with the antibiotic-
(Continued on next page)
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ing factor inﬂuencing the MDM inﬂammatory response. We therefore assessed pneu-
molysin activity in the TIGR4 Δcps mutant strain by using a red cell lysis assay and a
double-knockout Δply Δcps strain as a control. These data showed no signiﬁcant
differences in red cell lysis between TIGR4 wild-type and TIGR4 Δcps strains (Fig. S1C).
Compatible with recent data showing that pneumolysin inhibits production of proin-
ﬂammatory cytokines (38), there was increased production of IL-6 and TNF when MDMs
were incubated with pneumolysin-deﬁcient strains, with no differences seen between
the wild-type and unencapsulated strains (Fig. S1D and E). These data show that the
increased production of inﬂammatory cytokines in response to encapsulated strains
compared to unencapsulated strains is unlikely to be related to the effects of pneu-
molysin.
DISCUSSION
Multiple cell surface and intracellular signaling pathways have been identiﬁed that
lead to an inﬂammatory response when triggered by bacterial interactions with mac-
rophages (6, 8, 10, 20–22, 24, 39–41). The dominance of speciﬁc pathways in response
to particular pathogens will inﬂuence disease pathogenesis, but there are few pub-
lished data on the relative contributions of intra- and extracellular pathways for
inﬂammatory responses to bacterial pathogens. Here, we have investigated the con-
tribution of intracellular bacteria to the macrophage inﬂammatory response to S.
pneumoniae using differences in susceptibilities to phagocytosis of encapsulated and
unencapsulated S. pneumoniae. We have made two major perhaps unexpected obser-
vations: (i) the early macrophage proinﬂammatory cytokine response to S. pneumoniae
is mainly driven by extracellular bacteria, with little effect of internalized bacteria, and
(ii) for three of the four serotypes investigated, encapsulated bacteria are proinﬂam-
matory in comparison to their isogenic unencapsulated derivatives.
The dominant role of extracellular bacteria for the macrophage inﬂammatory re-
sponse to S. pneumoniae was suggested by the reduced inﬂammatory responses to the
unencapsulated strain despite the increased susceptibility of this strain to phagocytosis
compared to encapsulated S. pneumoniae. These results were supported by data
obtained after nonlytic killing of extracellular bacteria using gentamicin, inhibiting
phagocytosis using cytochalasin D, and using opsonized bacteria. Both the transcrip-
tomic and supernatant cytokine level data demonstrate that production of protective
inﬂammatory cytokines by macrophages infected with S. pneumoniae was independent
of phagocytosis and internalization. These results contrast strongly for data obtained
from another extracellular Gram-positive pathogen, Staphylococcus aureus, for which
TNF and other inﬂammatory cytokine responses depended on a combination of
extracellular and intracellular TLR activation (25). In contrast to our data, when phago-
cytosis of S. aureus was blocked, there were reductions in macrophage cytokine
responses, and a mutant S. aureus strain that was more sensitive to intraphagosome
degradation caused increased inﬂammatory responses (25, 26). Given the similarities
FIG 6 Legend (Continued)
supplemented data as a checked bar, with means  SEM from 4 experiments shown, as analyzed by unpaired t test. (B)
MDMs were incubated with bacteria for 4 h at an MOI of 10, then medium or gentamicin was added, and supernatant was
analyzed for TNF levels at subsequent time points. WT TIGR4 data are shown as black bars and TIGR4 Δcps data as gray
bars, displayed as means  SEM from 3 experiments, as analyzed by t test. (C) MDMs were incubated with 10 M
cytochalasin D or medium for 30 min and then incubated with TIGR4 or TIGR4 Δcps, and the antibiotic protection assay
was used to determine numbers of internalized bacteria. Box and whisker plots of median and range of experiments are
shown with TIGR4 data as a black box and cytochalasin D-treated cell data as a checked box, as analyzed by Mann-Whitney
U test. (D and E) MDMs were incubated with ﬂuorescently labeled TIGR4 (in green) at an MOI of 10 after preincubation
with medium only or 10 M cytochalasin D and imaged on a high-throughput microscope after 2 h, with nuclei in blue
and with external bacteria in yellow. (D) Representative image of TIGR4 only and (E) TIGR4 plus cytochalasin D. (F and G)
MDMs were incubated with controls or bacteria at an MOI of 10 for 6 h after preincubation with medium or 10 M
cytochalasin D, and (F) TNF and (G) IL-6 were measured in supernatant. Data are presented as mean  SEM from at least
3 experiments, as analyzed by unpaired t test. (H and I) Bacteria were incubated with pooled human serum for 30 min,
before incubation with MDM at an MOI of 10 for 6 h, and then supernatant (H) TNF and (I) IL-6 were measured. The data
are presented as means SEM from at least 3 experiments, as analyzed by 2-way ANOVA and Tukey’s multiple-comparison
test.
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between S. aureus and S. pneumoniae in disease pathogenesis and the PRRs they are
known to activate (42–44), the contrast between them in mechanisms driving macro-
phage inﬂammatory responses is surprising. Phagocytosis by innate immune cells also
induced more inﬂammation for the spirochete Borrelia burgdorferi (45, 46). One differ-
ence in the biology of these pathogens that might be relevant is that the majority of
phagocytosed S. pneumoniae cells are killed within 4 h (Fig. 1), whereas S. aureus is able
to survive in signiﬁcant numbers for at least 24 h (25, 26). Host cells scale their
inﬂammatory response to match the degree of threat from the invading pathogen,
which for S. pneumoniae could potentially lead to the reduced responses to internalized
bacteria reﬂecting this pathogen’s relatively poor intracellular survival (47).
FIG 7 Mean gene expression of MDMs incubated with WT TIGR4 or the Δcps mutant (6 donors each),
with the least-expressed genes in blue and the most-expressed genes in red. They are displayed in gene
order by most upregulated genes at the top, with TIGR4 stimulated compared to unstimulated (Unstim).
The expression of two important anti-inﬂammatory cytokines is also displayed in two separate rows. In
the relevant experiments, MDMs were preincubated with 10 M cytochalasin D for 30 min, which was
washed off, before the addition of bacteria at an MOI of 10. (B to D) MDMs were incubated with TIGR4
(black bars) or TIGR4 Δcps (gray bars) at an MOI of 10 for 4 h, and lysates were analyzed by qPCR for (B)
TNF, (C) IL-1, and (D) IL-6. The mean  SEM ΔCT from 4 experiments is displayed, as analyzed by
unpaired t test.
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As the capsule blocks S. pneumoniae interactions with MDM phagocytic receptors,
our initial hypothesis was that the presence of the capsule would reduce proinﬂam-
matory signaling by macrophages due to reduced internalization and inhibition of
bacterial-host interactions with external proinﬂammatory PRRs such as TLR2, similar to
the effect of the capsule for some other pathogens (48–52). However, unexpectedly,
MDMs incubated with encapsulated S. pneumoniae secreted higher levels of TNF (and
to a lesser extent IL-1 and IL-6) and had increased expression of a range of proin-
ﬂammatory and chemokine genes, including TNF, IL-1, IL-6, IL-23A, CXCL1, and CXL3.
During culture with MDMs, encapsulated S. pneumoniae CFU increased over time
compared to the unencapsulated strain, which probably reﬂects the increased suscep-
tibility of the latter to phagocytosis. However, several strands of evidence support that
the differences in the MDM inﬂammatory response between the encapsulated and
unencapsulated strains were not purely related to differences in CFU. These included
the following: (i) multiple MOI, which showed that increased TNF responses to encap-
sulated S. pneumoniae persisted when MDMs were incubated with 1/10 or 1/100 the
number of TIGR4 bacteria compared to TIGR4 Δcps; (ii) killing extracellular S. pneu-
moniae using gentamicin after 4 h of incubation, when there were no signiﬁcant
differences in CFU between the TIGR4 and TIGR4 Δcps strains, still caused large
differences in TNF responses, and (iii) repeating the experiments with three additional
S. pneumoniae serotypes, two of which also showed increased inﬂammatory responses
FIG 8 (A and B) MDMs were incubated with wild-type bacteria (serotypes 2, 6B, and 23F), with WT data
shown as black bars and isogenic capsule-deﬁcient mutant data as gray bars, for 6 h at an MOI of 10, and
supernatants were analyzed for (A) TNF and (B) IL-6. The data are displayed as means SEM from at least
3 experiments, as analyzed by unpaired t test.
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to the encapsulated strain compared to the unencapsulated mutant derivatives. In
addition, an important observation is that only a small number of genes showed
differences in transcriptional responses between the TIGR4 and TIGR4 Δcps strains, and
these were largely limited to inﬂammatory response genes, whereas broader changes
across the whole MDM transcriptional response to S. pneumoniae might be expected if
the differences were being driven by CFU alone. Increases in host transcriptional
responses have also been described when encapsulated serotype 2 S. pneumoniae cells
were incubated with human pharyngeal epithelial cells compared to the unencapsu-
lated strain (53).
Our data using mouse infection models suggested the increased inﬂammatory
responses to encapsulated bacteria could be relevant during disease. There was an
increased early BALF TNF response after infection with the TIGR4 strain compared to
infection with the TIGR4 Δcps strains in a model of early pneumonia, with differences
persisting when using different inoculum doses, nonreplicating bacteria, and at time
points when TIGR4 and TIGR4 Δcps strains showed no signiﬁcant differences in BALF
CFU (e.g., 4 h data after low-dose infection). However, the mouse data need to be
interpreted cautiously as even when similar BALF CFU occur for the TIGR4 and TIGR4
Δcps strains at a single time point, the different inoculum sizes needed to achieve this
mean the mice would have been exposed to markedly different bacterial loads over the
total duration of the infection.
FIG 9 (A and B) BMDMs from wild-type or TLR2 knockout C57BL/6 mice were incubated with controls,
WT TIGR4, or the TIGR4 Δcpsmutant at an MOI of 10 for 4 h. Levels of (A) TNF and (B) IL-6 were measured
in supernatant and are displayed as means  SEM from 3 experiments, as analyzed by unpaired t test.
(C) HEK TLR2 cells were incubated with controls, PPS at various concentrations, or bacteria at various MOI
for 16 h. Supernatant was analyzed for absorbance at 490 nm, and results are displayed as means  SEM
from 3 experiments, with WT TIGR4 data shown as black bars, TIGR4 Δcps data as gray bars, and puriﬁed
PPS data as hatched bars. Analysis was by 1-way ANOVA and Tukey’s multiple-comparison test.
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These results suggest that as well as assisting immune evasion, the capsule also
promotes a stronger inﬂammatory response, which mouse data suggest could poten-
tially aid S. pneumoniae transmission (54). Although inﬂammation is essential for control
of S. pneumoniae infections (4–7, 10, 11), this effect of the capsule in promoting
inﬂammation could also exaggerate the severity of invasive infections by contributing
to the development of ARDS or septic shock and leading to more tissue damage during
pneumonia (55) and meningitis (56).
The mechanism by which encapsulated S. pneumoniae cells stimulate a stronger
MDM inﬂammatory response remains unclear. We conﬁrmed published data that the
puriﬁed capsule has minimal effect on inﬂammatory cytokine release (33–35), with
residual responses after inhibition of LPS responses only to very high nonphysiological
concentrations of capsular material. Furthermore, expression of the S. pneumoniae
serotype 4 capsule did not increase the inﬂammatory response to S. mitis. In a reporter
assay, capsule material did not stimulate a TLR2 response, and encapsulated and
unencapsulated S. pneumoniae cells were able to cause similar levels of TLR2 stimula-
tion. One possible explanation is that the increase in intracellular bacteria for the
unencapsulated strains inhibited inﬂammatory cytokine responses to S. pneumoniae,
but preventing phagocytosis did not reduce the differences between TIGR4 and TIGR4
Δcps in inﬂammatory responses at qPCR, whole-genome transcriptional, and secreted
protein levels.
In summary, we have shown that in contrast to S. aureus, macrophage-dependent
inﬂammatory responses to S. pneumoniae capsule are largely dependent on extracel-
lular bacteria. In addition, we have shown an unexpected proinﬂammatory effect on
macrophage responses of incubation with encapsulated compared to unencapsulated
S. pneumoniae. Further investigation will be necessary to identify why the early MDM
inﬂammatory response to S. pneumoniae infection is largely independent of intracel-
lular signaling pathways and is stronger in response to encapsulated compared to
unencapsulated bacteria.
MATERIALS AND METHODS
Bacterial strains and culture. Experiments were performed using the wild-type serotype 4 TIGR4 S.
pneumoniae strain and its otherwise isogenic unencapsulated mutant derivative, TIGR4 Δcps (a kind gift
from J. Weiser) (57). ΔpabB mutants (58), which do not replicate without an exogenous source of
para-aminobenzoic acid, were used to address differences in bacterial numbers in vivo. S. pneumoniae
cells were cultured in THY broth (Todd-Hewitt broth supplemented with yeast extract) or on 5% blood
Columbia agar plates (Sigma-Aldrich, Gillingham) at 37°C in 5%CO2. S. pneumoniae cells were labeled
ﬂuorescently for uptake experiments using 6-carboxyﬂuorescein succinimidyl ester (FAM-SE [Molecular
Probes, Eugene, OR, USA]) as previously described (59). The S. mitis wild-type strain, S. mitis Δcps mutant,
and an S. mitis mutant strain expressing the S. pneumoniae serotype 4 capsule were used to address the
effect of capsule in a nonpathogenic species (37). Additional experiments used encapsulated and
unencapsulated strains (made by deletion of cps Janus cassette as previously described [57] or of cpsD
for the serotype 2 strain [60]) of serotypes 2 (D39), 6B (ST138 clinical isolate), and 23F (ST36 clinical
isolate). A TIGR4 Δcps Δply strain was created by using DNA from TIGR4 Δcps and TIGR4 Δply (a kind gift
from Tim Mitchell) strains, using antibiotic resistance cassettes to allow selection of double-knockout
mutants (61).
Cell culture. Blood from healthy volunteers was layered onto Ficoll-Paque Plus (GE Healthcare Life
Sciences, Hatﬁeld, United Kingdom) and centrifuged to obtain peripheral blood mononuclear cells
(PBMCs). Adherent cells were differentiated in Roswell Park Memorial Institute medium (RPMI), supple-
mented with human macrophage colony-stimulating factor (M-CSF) and autologous serum, into
monocyte-derived macrophages (MDMs) as previously described (62). Experiments were carried out in
RPMI supplemented with 5% pooled human AB serum (Sigma-Aldrich, Gillingham, United Kingdom).
Experiments using MDMs were approved by the joint University College London/University College
Hospitals National Health Service Trust Human Research Ethics Committee (reference no. 3076/001). RAW
264.7 cells, a murine cell line with a macrophage-like phenotype, were cultured in RPMI (Gibco,
Loughborough, United Kingdom) supplemented with fetal bovine serum (FBS [Lonza, Blackley, United
Kingdom]) and L-glutamine. HEK 293 cells, a human embryonic kidney cell line, stably transfected with
TLR2 and CD14 (Invivogen, San Diego, CA) were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM
[Gibco, Loughborough, United Kingdom]) supplemented with FBS and L-glutamine. THP-1 cells, a human
monocyte cell line, were cultured in RPMI and FBS with L-glutamine. Bone marrow was extracted from
6- to 8-week-old C57BL/6 WT and TLR2/ mice (Jackson ImmunoResearch Laboratories) and differen-
tiated into bone marrow-derived macrophages (BMDMs) for 7 days in L929-conditioned medium using
standard protocols (63).
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Red cell lysis assay. Two percent horse blood was added to U-bottom 96-well plates with serial
dilutions of bacteria or 0.5% saponin (positive control) in phosphate-buffered saline (PBS). The plates
were incubated at 37°C in 5% CO2 for 30 min and then centrifuged. The supernatant was aspirated and
placed in a ﬂat-bottom 96-well plate (Brand, Wertheim, Germany), and absorbance at 540 nm was
measured on a microplate reader. Absorbance reﬂected free hemoglobin liberated from lysed cells (64).
Phagocytosis assays. Antibiotic protection assays were carried out using 200 g/ml gentamicin as
previously described (65). In brief, this involved incubating MDM or RAW cells with bacteria with or
without antibiotics, washing the cells after 2 h, and then plating the lysate for bacterial counts to
measure internal bacteria versus adherent plus internal bacteria. Intracellular survival experiments were
performed using THP-1 cells, with MOI resulting in approximately equal uptake per THP-1 cell of TIGR4
or TIGR4 Δcps bacteria, followed by addition of gentamicin (200 g/ml) after 30 min of incubation to kill
extracellular bacteria and then addition of 2% saponin at the speciﬁed time points to lyse the cells for
plating to obtain bacterial CFU. Microscopy phagocytosis assays were performed using FAM-SE-labeled
bacteria opsonized in human serum, staining of external bacteria with phycoerythrin (PE)-labeled goat
anti-human IgG (Sigma-Aldrich, Gillingham), and DAPI (4=,6-diamidino-2-phenylindole) staining of the
nuclei, using a Hermes microscope for imaging (Biotech-Europe, Prague, Czech Republic). Images were
analyzed on Metamorph (Metamorph, Inc.) software. Flow cytometry phagocytosis assays were per-
formed using FAM-SE-labeled S. pneumoniae as previously described (59).
TLR2 reporter assay. HEK TLR2 cells were resuspended in HEK-Blue detection medium (Invivogen,
San Diego, CA), added to 96-well tissue culture plates (Nunc, Roskilde, Denmark), and then stimulant was
added. The optical density, reﬂecting TLR2 activation, was measured on a microplate reader (Versamax,
Sunnyvale, CA, USA).
Cytokine ELISA. Enzyme-linked immunosorbent assays (ELISAs) were carried out using R&D Systems
(Abingdon) Duo kits as per the manufacturer’s instructions.
qPCR. RNA extraction of MDM for qPCR or microarray was performed with Qiagen RNeasy minikit
(Qiagen, Hilden, Germany) as per the manufacturer’s instructions. Contaminating DNA was eliminated
with Precision DNase (Primer Design, Southampton, United Kingdom). RNA concentration and quality
was measured using a Nanodrop 3000 and a ratio of absorbance of 260:280 (aiming for 2.0). cDNA was
synthesized in clear PCR plates (Thermoscientiﬁc, Loughborough, United Kingdom) with qScript cDNA
SuperMix (QuantaBiosciences, Beverley, MA, USA). TaqMan gene expression assays were run on a
Realplex Mastercycler (Eppendorf, Stevenage, United Kingdom). The cycle threshold (CT) was determined
for all samples and analyzed by ΔCT for relative expression values, with the GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) gene used as a housekeeping gene (66).
Microarray whole-genome transcription. Total RNA was puriﬁed from MDM lysates, collected as for
qPCR, and processed for Agilent microarrays as previously described (66, 67).
A microarray (Agilent, Santa Clara, CA, USA) platform was used to perform whole-genome transcrip-
tional analysis of MDMs incubated with bacteria. An Agilent Low-input Quick Amp labeling kit was used
for two-color microarray-based gene analysis on an Agilent microarray scanner. Data from the microarray
were normalized as previously described (70) and analyzed using a multiexperiment viewer (Sourceforge)
and Bioagilent insert for R (R Project). Bioinformatic analysis was performed using the online analysis
tools Innate DB (68), Gephi (v0.82) for network visualization (https://gephi.org/), and oPOSSUM (69).
Mouse infection model. Murine work was carried out within Home Ofﬁce guidelines under project
license PPL70/7361. Female CD1 5-week-old mice (Charles Rivers) were anesthetized with isoﬂurane and
inoculated intranasally with 50 l of bacterial suspension as previously described (17, 32). In speciﬁc
experiments, antibodies or inhibitors were administered intranasally under isoﬂurane anesthesia or
intraperitoneally. At speciﬁed time points, the mice were euthanized with intraperitoneal pentobarbital,
and bronchoalveolar lavage ﬂuid (BALF), blood, and lungs (homogenized using cell strainers [Falcon,
Corning, NY, USA]) were obtained to calculate bacterial CFU by plating serial dilutions. BALF cell counts
were counted using a hemocytometer.
Statistical analysis. Statistical analyses of data were performed with GraphPad Prism V7 (La Jolla, CA,
USA). Data were analyzed by unpaired t test when comparing 2 groups and 1- or 2-way analysis of
variance (ANOVA) with Tukey’s or Sidak’s multiple-comparison test, respectively, for multiple groups.
Nonparametric data (e.g., CFU) were analyzed by Mann-Whitney U test when comparing 2 groups, and
Kruskal-Wallis with Dunn’s multiple-comparison test for multiple groups. Statistically signiﬁcant differ-
ences in microarray data were identiﬁed by unpaired t test. Z score analysis was performed on
transcription factor binding bioinformatics.
Data availability. All microarray data used in this study are available in ArrayExpress (https://www
.ebi.ac.uk/arrayexpress/) under accession no. E-MTAB-5894.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
.02144-19.
FIG S1, TIF ﬁle, 2.8 MB.
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